Browsing: GLP1

1 medications, known for treating diabetes and obesity, may also help combat addiction, according to a new study by Washington University School of Medicine in St. Louis. These drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, are linked to reduced substance use disorders and serious outcomes across various addictive substances

It has been 12 years since the first GLP-1 receptor agonist, liraglutide (Saxenda), was approved as a weight loss medication. This breakthrough was followed in 2021 by the approval of semaglutide (Wegovy) and in 2023 by the approval of tirzepatide (Zepbound), which have transformed obesity treatment

Federal regulators are turning up the heat on sellers of copycat weight-loss drugs. Earlier this summer, theFood and Drug Administration sent warning letters to dozens of companies marketing compounded GLP-1s over misleading advertising

Usage of GLP-1 drugs surged in recent years, rising over 140% from 2022 to 2024, which had a significant impact on hospital services aimed at treating obesity. In that same timeframe, bariatric surgery volumes fell 34 percent

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Press release Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Analysis Highlights Growth To $32.86 Billion By 2030 At 16.2% CAGR 08-19-2026 12:56 PM CET | Health & MedicinePress release from: The Business Research Company Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market The market for glucagon-like peptide…

We speak to doctors, nutritionists, health coaches and people taking the medication to find out what the 2026 Ozempic diet really looks likeIllustration by THR India Updated on: 21 Aug 2026, 9:13 am

CINCINNATI (WKRC) – GLP-1 weight loss medications are helping some patients see improvements beyond the number on the scale, including relief from symptoms tied to vascular problems and inflammation, according to a Cincinnati vascular surgeon and one of his patients

GLP-1 receptor agonist drugs have long been used to treat diabetes and, more recently, obesity. Now, researchers are studying whether the medications could also help prevent opioid addiction relapse

When GLP-1 weight loss medications first began gaining mainstream attention, the food and beverage industry was largely asking a defensive question: what happens if consumers simply eat less? 

Millions of people in the U.S. are taking injectable GLP-1 drugs for weight loss, and now there is even a CMS subsidy for certain GLP-1 medications. But the drug hasn’t had much of an impact on senior living operations or residents thus far